6CM
WHWK

683 Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

683 Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-80,000
Closed -$117K – 155
2024
Q2 		$117K Sell
80,000
-120,000
-60% -$222K 0.01% 111
2024
Q1 		$468K Hold
200,000
– – 0.03% 97
2023
Q4 		$404K Buy
+200,000
New +$839K 0.03% 97
2022
Q2 		– Sell
-18,025
Closed -$306K – 333
2022
Q1 		$306K Hold
18,025
– – 0.02% 234
2021
Q4 		$435K Buy
+18,025
New +$453K 0.02% 213

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

683 Capital Management's WHWK Position: Q3 2024 in Review

683 Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q3 2024, closing a stake of 80,000 shares — an estimated $117K sold.

683 Capital Management first reported a position in WHWK in Q4 2021 and held it in 5 quarters. The position peaked at $468K in Q1 2024. 52 funds tracked by Wall St. Rank hold WHWK as of Q3 2024.

  • 683 Capital Management reported no remaining Whitehawk Therapeutics position as of Q3 2024 after selling out during the quarter.
  • 683 Capital Management sold 80,000 Whitehawk Therapeutics shares in Q3 2024, an estimated $117K.
  • 683 Capital Management first reported a position in Whitehawk Therapeutics in Q4 2021 and held it in 5 quarters.
  • 683 Capital Management's Whitehawk Therapeutics position peaked at $468K in Q1 2024.
  • 52 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2024.

Based on 683 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.